Skip to main content

Sources last read

Oncology · approved care and active research

Peptides and cancer: four different things

Peptides already have real roles in cancer care. The roles are not alike: one approved drug carries radiation. Another copies a hormone signal. A custom vaccine is still in a trial. LL-37 was tested in four people.

Source: Two FDA labels, one NCI guide and two trial records, read 2026-08-16

What matters first

Approved roles
Radiation delivery and hormone signaling
Custom peptide vaccine
Still in a clinical trial
LL-37 study
Four participants
Rule
Judge the exact treatment and evidence stage

“Peptide” tells you what a molecule is made from. It does not tell you what the treatment does, which tumor it targets or whether it has passed a clinical trial. Start with the role and the evidence stage.

The evidence-state map

Same word, four different jobs

Each card keeps the example, current status, finding and stopping point together. That is the shortest way to avoid turning early research into a treatment claim.

01FDA-approved for a named cancer

A peptide carries radiation to a tumor receptor

Lutathera (lutetium Lu 177 dotatate)

What studies show
The label calls it a radioactive somatostatin analog. It targets gastroenteropancreatic neuroendocrine tumors that carry the right receptor.
Do not carry it past
This is a hospital radiopharmaceutical for receptor-positive tumors, not evidence that an unrelated wellness peptide treats cancer.
02FDA-approved for a named cancer

A peptide analog acts as the drug itself

Somatuline Depot (lanreotide)

What studies show
The label covers a defined group of gastroenteropancreatic neuroendocrine tumors. They may be advanced, metastatic or unable to be removed by surgery.
Do not carry it past
An approval for a defined neuroendocrine-tumor population does not make peptide products a general cancer-treatment class.
03Recruiting phase 1 · no results

Peptides teach the immune system what to recognize

Personalized synthetic long-peptide vaccine

What studies show
NCT06529822 plans to enroll 64 people. It asks about safety. It also asks if each custom vaccine can be made and delivered on time.
Do not carry it past
A recruiting feasibility study has no treatment result. NCI describes antigen-based cancer vaccines as experimental.
04Completed phase 1/2 · 4 people

A familiar research peptide is injected into a tumor

LL-37 in melanoma

What studies show
NCT02225366 enrolled four people. Its main outcome was the dose and side-effect boundary for shots into melanoma tumors.
Do not carry it past
A four-person dose-finding record does not establish that LL-37 treats melanoma, and it says nothing about routine injections elsewhere in the body.
Open the LL-37 record

The useful surprise

This is not a future-only field

Lutathera and lanreotide show two ways these drugs already appear in cancer care. One carries radiation to a tumor with the right receptor. The other copies a hormone signal.

The approval belongs to the exact drug, tumor type, route and evidence package on the label. It does not transfer to another peptide because both are made from amino acids.

How to read the next headline

Five questions before “peptide” becomes “cancer treatment”

  1. What is the peptide doing? It may be the drug, carry radiation or present a tumor target to immune cells.
  2. Which tumor and marker? A receptor-positive neuroendocrine tumor is not “cancer” in general.
  3. What stage is the evidence? FDA approval, recruiting phase 1 and a completed four-person study are different answers.
  4. What was the main outcome? Safety or dose finding cannot be restated as tumor control.
  5. Does the claim match the route? An injection into a tumor does not establish a routine injection under the skin.

Keep reading

Browse all peptide and GLP-1 guides

15 plain-language guides, grouped by the question a reader brings rather than by the source behind it.

Original findings you can inspect row by row

The answer stays beside the source read, the method, the limits and the complete table.

Which healing and recovery claims have a trial

No completed trial in an injured person — see which popular claims still have no human evidence.

The sourcing rules behind every figure here

Why a label band and a trial percentage are never averaged together.

The full page index behind these pages

The spine every dosing, safety and calculator page reads from.

5primary sources, each with the day we read it — open the documents used on this page